Injective (INJ) is currently trading at $2.87, reflecting a slight decline of 1.55% over the last 24 hours. The daily price range has been narrow, with a high of $2.92 and a low of $2.84, indicating reduced volatility and market interest.

Volume over the past 24 hours is reported at approximately 35.6 million, representing a volume-to-market cap ratio of 12.43%. This suggests that trading activity remains somewhat significant, but the recent negative price trends may deter new investments.

Technical indicators show that short-term moving averages (8, 13, 21 SMA) are all positioned below the current price, indicating bearish momentum, particularly the 55 SMA at $2.98, which is 3.65% above the current price. The RSI metrics, with the 1-hour RSI at 36 and the 7-day RSI at 47, suggest that INJ is approaching oversold territory, yet still lacks sufficient bullish momentum for a rebound.

Fundamentally, the 7-day price change stands at -3.37%, while the 14-day and 30-day price changes are significantly more negative at -28.14% and -13.05%, respectively. This sustained downtrend raises concerns about investor confidence and suggests a longer-term bearish outlook.

Given the proximity to support levels and the oversold RSI readings, a potential short-term rebound could occur, but the overall trend remains negative. The absence of any major positive catalysts or shifts in market sentiment further supports a cautious approach.

In conclusion, the current analysis indicates a Sell rating for Injective (INJ). The ongoing downtrend and lack of momentum suggest that it is not an optimal time to enter the market, and investors should consider reducing their positions or waiting for clearer bullish signals before making new investments.